Dr. Gregory Bix
Director, Clinical Neuroscience Research Center; Professor & Vice Chair of Clinical & Translational Research
Biography
Dr. Bix is currently the director of the Clinical Neuroscience Research Center, Vice-Chair of Clinical & Translational Research, Department of Neurosurgery and the Vada Odom Reynolds Chair in Stroke Research at Tulane University.
He also holds the position of Clinical Lecturer (honorary) at the University of Glasgow, adjunct Professor at the Queensland University of Technology, Professor (honorary) at the University of Manchester and is a Fellow of the American Heart Association.
Dr. Bix completed his clinical and research training at Baylor College of Medicine, the University of Pennsylvania and Thomas Jefferson University.
He has published more than 50 papers in reputed journals, won several research awards and is the inventor on several patents for his various scientific discoveries.
Dr. Bix is currently the P.I. on 4 NIH R01 grants, 1 NIH R21 and co-Investigator on two NIH R44 SBIR grants. His research focus is in the role and therapeutic potential of the extracellular matrix and its receptors in stroke and vascular dementia.
Education
Baylor College of Medicine
Baylor College of Medicine
University of Pennsylvania
Thomas Jefferson University
Articles
Perlecan Domain-V Enhances Neurogenic Brain Repair After Stroke in Mice
The extracellular matrix fragment perlecan domain V is neuroprotective and functionally restorative following experimental stroke.
Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin
The Control anti-αvβ3 micrograph in the original version of Fig. 5 A was a duplicate of the Control micrograph in Fig. 6 A.
Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents
Stroke is the leading cause of long-term disability and the third leading cause of death in the United States.
Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism
The antiangiogenic approach to controlling cancer requires a better understanding of angiogenesis and the discovery of new compounds that modulate this key biological process. Here we investigated the role of endorepellin, an angiostatic protein fragment that is derived from the C-terminus of perlecan, a heparan sulfate proteoglycan, in controlling tumor angiogenesis in vivo.
